TikkunLev Therapeutics is on a mission to revolutionize the treatment of heart failure by targeting the underlying biology of failing heart muscle.
Founded on the pioneering research of Professor Robin Shaw M.D., Ph.D., our lead program, TLT-101, is a precision therapy that targets the underlying protein trafficking defects in heart failure. Extensive preclinical data demonstrate an unprecedented efficacy and safety profile with our therapeutic approach. TLT-101 is in IND-enabling development for non-ischemic dilated cardiomyopathy (DCM), a severe and progressive disease that is a leading cause of heart failure.
With cardiovascular disease remaining the leading global cause of death and 1 in 4 people expected to develop heart failure, our innovative approach aims to repair the heart and transform lives.
Company Details
- Employees
- 1
- Address
- The Underlying Causes Of Heart Failure.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.tikkunlev.com
- Keywords
- coordinating treatment.
Tikkunlev Therapeutics Questions
Tikkunlev Therapeutics's website is http://www.tikkunlev.com
Tikkunlev Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tikkunlev-therapeutics
Tikkunlev Therapeutics has
1 employees.
View email and phone details for 1
employees at Tikkunlev Therapeutics.
Tikkunlev Therapeutics's industry is
Biotechnology Research
Tikkunlev Therapeutics's top competitors are
Alyssum Therapeutics,
Ottimo Pharma,
Integrated Biosciences, Inc.,
Booster Therapeutics,
City Therapeutics,
Tolerance Bio,
Holobiome,
Kailera Therapeutics,
Judo Bio,
Archon Biosciences.
Tikkunlev Therapeutics's categories are Biotechnology Research
